Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

up> ER has not been evaluated in patients with a predisposition to a seizure disorder, and such patients were excluded from clinical studies. As with other opioids, NUCYNTA® ER should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures.
  • Cases of life-threatening serotonin syndrome have been reported with the concurrent use of tapentadol and serotonergic drugs. Serotonergic drugs comprise selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, drugs that affect the serotonergic neurotransmitter system (eg, mirtazapine, trazodone, and tramadol), and drugs that impair metabolism of serotonin (including MAOIs). This may occur within the recommended dose. Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea), and can be fatal.
  • Withdrawal symptoms may occur if NUCYNTA® ER is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely, hallucinations. Withdrawal symptoms may be reduced by tapering NUCYNTA® ER.
  • A study with the immediate-release formulation of tapentadol in subjects with hepatic impairment showed higher serum concentrations of tapentadol than in those with normal hepatic function. Tapentadol should be used with caution in patients with moderate hepatic impairment.
  • NUCYNTA® ER has not been studied in patients with severe hepatic impairment, and use in this population is not recommended.
  • Like other drugs with mu-opioid
    '/>"/>

  • SOURCE Janssen Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
    2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
    4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
    5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
    6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
    7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
    8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
    10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
    11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
    (Date:8/1/2014)... Aug. 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... pivotal Phase 3 study evaluating ISIS-SMN Rx in ... genetic cause of infant mortality. Isis plans to dose ... few weeks, at which time Isis will earn an ... Idec. The Phase 3 study, ENDEAR, is the first ...
    (Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
    Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
    ... Ala., May 7 BioCryst Pharmaceuticals (Nasdaq: BCRX ... first quarter 2009 financial results will be released on Friday, ... a conference call and Web cast at 8:30 a.m. Eastern ... on the Company,s programs. The call will be led ...
    ... The Abbott RealTi m e HIV-1 Assay and Abbott ... protocol for viral load testing in HIV/AIDS clinical trials sponsored ... This recommendation was made by the Cross-Network Laboratory Focus Group ... HIV/AIDS clinical trials networks. The LFG recently issued a consensus ...
    Cached Medicine Technology:BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 3
    (Date:8/1/2014)... (PRWEB) August 01, 2014 Summer is here, ... most active during the summer, and they can be a ... is ready to help all their customers get rid of ... 3,000 and 6,000 eggs in the summer, which is why ... live in tall grass and woodland areas and carry a ...
    (Date:8/1/2014)... Illinois (PRWEB) August 01, 2014 As ... across the country, Ronald E. Johnson, Jr. has been ... by AndroGel and other testosterone medications. Since the Fall ... Johnson, P.S.C. have worked diligently to investigate and prosecute ... pulmonary embolisms, and blood clots as a result of ...
    (Date:8/1/2014)... Writing down fears, emotions and the benefits of a ... cancer survivors, according to a study conducted by a ... "The key to developing an expressive writing intervention is ... journal recording facts and events. Writing a journal can ... evidence to determine whether it,s effective or not," said ...
    (Date:8/1/2014)... 2014 Growing prevalence of chronic ... reforms are boosting healthcare market growth, although a ... and increasing generic consumption is a major challenge. ... in 2013, having grown at a Compound Annual ... implementation of the Health Transformation Program (Saglikta Donus, ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 Hot off the ... destination spa category of the World’s Best Awards by ... a month-long celebration of National Relaxation Day (technically August 15). ... series of MAJOR experts to help guests celebrate relaxation throughout ... it is for health and wellness to carve out time ...
    Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
    ... of remittances shines spotlight on companies engaged in ... those efforts, - Economic issues top ... of origin for the 3x1 and 4+1 programs. - Secure,delivery, seen as most important ... would encourage senders to use companies that ...
    ... Health and Human Services published an update to its ... and Dependence,which contains revised and improved recommendations to providers ... quitting. The,guideline also confirms that there has never been ... With the release of these new guidelines, smokers ...
    ... following is a,statement by William V. Corr, Executive ... smoking cessation released today by the U.S. Public,Health ... 45 million,smokers that they have more scientifically proven ... their health than ever before, including safe,and effective ...
    ... An updated clinical,practice guideline released today by the ... medication treatments that are effective for,helping people quit ... JAMA includes,a commentary that urges clinicians to use ... use of tobacco., Treating Tobacco Use and ...
    ... results of sub-analyses of dose-titration study and long-term, ... open-label study presented today, WASHINGTON, ... in children, Attention Deficit Hyperactivity Disorder,(ADHD) is now known to be ... lifespan(1). In the US, the overall,prevalence of ADHD in adults is ...
    ... it helps ease the shock of trauma, study finds ... from post-traumatic stress disorder may ultimately benefit from a ... new research suggests. , The study findings are preliminary. ... a potent way to help PSTD patients through the ...
    Cached Medicine News:Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:New Smoking Cessation Guideline Confirms That Now is the Time to Quit Smoking 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 4Health News:New Evidence Provides Clinicians With Better Tools to Help Smokers Quit 2Health News:New Evidence Provides Clinicians With Better Tools to Help Smokers Quit 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 4Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 5Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 6Health News:Virtual Reality Therapy May Help PTSD Patients 2Health News:Virtual Reality Therapy May Help PTSD Patients 3